We report a case of a 3-year-old girl with generalized pustular psoriasis (GPP) and a compound heterozygous mutation within the IL36 receptor antagonist (IL36RN) gene at c.28C>T and c.115+6T>C, who was successfully treated using secukinumab monotherapy. The first dose of secukinumab (150 mg) was administered subcutaneously, followed by 75 mg of secukinumab subcutaneously once weekly for 4 weeks and then 75 mg every 4 weeks. The total course of treatment was 4 months, with a total of 8 doses. A PASI score of 75 and 100 was achieved at weeks 1 and 2, respectively, and maintained for 11 months of follow-up, without disease recurrence or adverse events.

中文翻译：

---

使用苏金单抗单药治疗成功治疗 3 岁女孩全身性脓疱型银屑病

我们报告了一例患有全身性脓疱性银屑病 (GPP) 和 IL36 受体拮抗剂(IL36RN)基因内 c.28C>T 和 c.115+6T>C复合杂合突变的 3 岁女孩病例，她是使用苏金单抗单药治疗成功。第一剂苏金单抗 (150 mg) 皮下给药，随后每周一次皮下注射 75 mg 苏金单抗，持续 4 周，然后每 4 周给药 75 mg。总疗程为4个月，共8剂。PASI 评分分别在第 1 周和第 2 周达到 75 和 100，并维持了 11 个月的随访，没有疾病复发或不良事件。